Harnessing the power of RNA epigenetics

Watch full video

STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.

Read more

RNA and RNA epigenetics

RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template for the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.

Read more

View video

News

STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes

STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK

Events

16 - 19th October 2019 | Heidelberg, Germany

EMBO|EMBL Symposia The Non-Coding Genome

26 - 30th October 2019 | Boston, US

ACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 2021 Dates To be Confirmed

Find out more